TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong · Delayed Price · Currency is HKD

9.38

-0.09 (-0.90%)

Sep 11, 2026, 4:08 PM HKT

HKG:2617 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	35.46	-	-	1.18	0.12
Revenue Growth	-	-	-	852.42%	-
Gross Profit	35.46	-	-	1.18	0.12
Operating Income	-273.17	-301.54	-291.77	-382.52	-312.36
Net Income	-268.56	-295.96	-274.61	-343.39	-251.94
Earnings Per Share	-0.67	-0.76	-0.72	-0.90	-0.70
EPS Growth	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Investments	925.22	489.39	573.93	838.72	984.35
Total Debt	5.61	1.65	4.37	4.81	2.69
Net Cash (Debt)	919.61	487.74	569.56	833.91	981.66
Net Cash Growth	88.54%	-14.37%	-31.70%	-15.05%	-
Net Cash Per Share	2.30	1.25	1.49	2.19	2.72

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Cash Flow	-	-253.51	-271.18	-319.33	-236.89
Capital Expenditures	-	-0.16	-0.77	-3.49	-2.02
Free Cash Flow	-	-253.68	-271.96	-322.81	-238.91
Free Cash Flow Growth	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Gross Margin	100.00%	-	-	100.00%	100.00%
Operating Margin	-770.47%	-	-	-32389.58%	-251900.00%
Pretax Margin	-757.48%	-	-	-29076.55%	-203180.65%
Profit Margin	-757.48%	-	-	-29076.54%	-203180.65%
FCF Margin	-	-	-	-27333.78%	-192667.74%

Valuation

Selected indicators aren't available for this stock.